Who is this relevant for?

  • Pharmaceutical buyers sourcing shortage medicines
  • Hospitals managing supply risk
  • Distributors monitoring sourcing opportunities

CDC has told U.S. tuberculosis programs to prepare for continued supply disruption across several first-line TB medicines, with rifampin remaining the most acute pressure point.

In its letter to state and local health departments, the agency said programs have reported difficulty accessing isoniazid, rifampin, rifapentine, ethambutol, and pyrazinamide. It linked those access problems to manufacturer exits, supply chain interruptions, uneven geographic distribution, erratic supply, rising costs, and limited active ingredients that may need to be imported.

That matters operationally because these are core TB products. CDC said unreliable supply has already forced some programs to revise treatment plans, priorities, and program practices.

Rifampin remains the clearest shortage signal

CDC noted that FDA has classified rifampin as in short supply since December 2021. At the time of the letter, FDA was not reporting shortages for isoniazid, ethambutol, or pyrazinamide.

For buyers and hospital teams, that distinction matters. A medicine does not need to appear on the FDA shortage list to create local disruption. CDC's message reflects that gap between national reporting and on-the-ground availability.

How CDC wants programs to respond

The agency set out a practical sequence for programs that cannot procure antituberculosis medicines:

  • check availability across all four major distributors
  • arrange loan and repayment agreements with other programs
  • explore direct shipments from manufacturers, including shipments arranged through distributors
  • pursue supply through the retail market
  • consult CDC project officers about stockpile access when there is an FDA-defined national shortage or when stockpiled drugs are nearing expiry

CDC said it released rifampin units from its TB Drug Stockpile to multiple programs earlier in the year. The stockpile also had isoniazid and rifampin on order.

This is a structured contingency model rather than a single-source fix. Programs are being pushed to widen their sourcing options before disruption reaches the patient level.

What this means for supply planning

The letter points to repeated local supply disruptions over the past two years and urges programs to build contingency plans for specific drugs. CDC also advised programs to consider backup suppliers where possible.

That puts supplier diversification at the center of TB procurement. For distributors, it highlights a market where local availability can shift even when a product is not formally listed as nationally short. For buyers, it reinforces the need to map alternatives by product, channel, and region instead of relying on one route to supply.

CDC also made clear that it cannot change national or regional supply levels or drug costs. The burden of continuity sits with local programs, distributor outreach, manufacturer coordination, and stockpile escalation where eligibility applies.

For operators dealing with shortage medicines, the CDC letter is a straightforward signal: first-line TB supply remains fragile, and continuity depends on active contingency sourcing rather than routine replenishment.